Abstract 2640
Background
Desmoid-type fibromatosis (DTF) is a rare, non-metastasising soft tissue tumour, which by local growth can significantly impact health related quality of life (HRQL). We aimed to identify the most important HRQL-issues of DTF patients.
Methods
DTF patients and health care professionals (HCPs) from the Netherlands and the United Kingdom individually ranked 124 issues according to their relevance. Patients also completed the European Organisation for Research and Treatment of Cancer QLQ-C30 core questionnaire (EORTC QLQ-C30). Outcomes of both groups were used to identify the most important HRQL-issues.
Results
The most highly ranked issues by patients (n = 29) were issues concerning ‘tumour growth’, ‘feeling that there is something in the body that does not belong there’, and ‘fear of tumour growth into adjacent tissues or organs’ with mean scores of 3.0, 2.9 and 2.8 respectively out of a total of 4 points. British patients scored higher on most issues compared to Dutch patients. Similarly, all HCPs (n = 31) gave higher scores on most issues compared to patients (total mean score of 2.3 versus a total mean of 1.9 for patients). The EORTC QLQ-C30 sum of scores was relatively high with a mean score of 77 points out of 100.
Conclusions
Patients affected by DTF experience psychological issues regarding the unpredictable tumour growth behaviour. Validation in a large international cohort is needed to devise a HRQL-questionnaire specific to DTF patients to fully address their needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Stichting Coolsingel Rotterdam.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract